Skip to main content
ROIV
NASDAQ Life Sciences

Director Keith Manchester Sells $32.6 Million in Roivant Shares Amidst Broader Insider Distribution

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Negative
Importance info
8
Price
$26.92
Mkt Cap
$18.93B
52W Low
$8.73
52W High
$27.94
Market data snapshot near publication time

summarizeSummary

Roivant Sciences Director Keith S. Manchester disposed of over $32.6 million worth of common shares, contributing to a significant pattern of insider selling at the company.


check_boxKey Events

  • Director Sells Significant Stake

    Keith S. Manchester, a Director of Roivant Sciences, sold 1,225,784 common shares through five open market transactions.

  • Substantial Transaction Value

    The total value of the shares sold amounted to $32,658,518, executed at prices ranging from $26.49 to $26.76 per share.

  • Sales Near 52-Week Highs

    The sales occurred between February 11-13, 2026, while the company's stock is trading near its 52-week high, potentially indicating insiders are locking in gains.

  • Part of Broader Insider Distribution

    This sale contributes to a pattern of over $74 million in net insider sales at Roivant Sciences over the past 90 days, indicating a wider trend of key personnel reducing their holdings.


auto_awesomeAnalysis

This substantial sale by Director Keith S. Manchester, totaling $32.6 million, represents a notable disposition of shares, particularly as it occurs while the stock is trading near its 52-week high. The transaction is part of a broader trend of insider selling at Roivant Sciences, with over $74 million in net sales by three active insiders in the last 90 days, including another significant sale by Director Daniel Allen Gold reported on the same day. This pattern of distribution by key personnel could signal a lack of conviction in the company's near-term prospects or a desire to lock in gains at elevated share prices. Investors should monitor future insider activity for further indications of sentiment.

At the time of this filing, ROIV was trading at $26.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.9B. The 52-week trading range was $8.73 to $27.94. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ROIV - Latest Insights

ROIV
Apr 20, 2026, 6:27 PM EDT
Filing Type: 4
Importance Score:
7
ROIV
Apr 02, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
ROIV
Apr 02, 2026, 5:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
ROIV
Mar 04, 2026, 3:04 PM EST
Source: Wiseek News
Importance Score:
9
ROIV
Mar 03, 2026, 5:11 PM EST
Source: Dow Jones Newswires
Importance Score:
8
ROIV
Mar 03, 2026, 7:23 AM EST
Source: Wiseek News
Importance Score:
9
ROIV
Mar 03, 2026, 7:13 AM EST
Filing Type: 8-K
Importance Score:
9
ROIV
Feb 19, 2026, 4:24 PM EST
Filing Type: 144
Importance Score:
7
ROIV
Feb 13, 2026, 9:02 PM EST
Filing Type: 4
Importance Score:
8
ROIV
Feb 13, 2026, 9:00 PM EST
Filing Type: 4
Importance Score:
8